Evidence map›Paper›PMID 40682676›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [

Holger Einspieler, Heidemarie Ofner, Marius Ozenil, Clemens P Spielvogel, Ilva Kristiana Langrate, Melanie R Hassler, Lukas Nics, Karsten Bamminger, Pascal A T Baltzer, Shahrokh F Shariat and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Holger EinspielerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Heidemarie OfnerDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Marius OzenilDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Clemens P SpielvogelDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Ilva Kristiana LangrateDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Melanie R HasslerDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Lukas NicsDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Karsten BammingerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Pascal A T BaltzerDepartment of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, 1090, Austria.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Marcus HackerDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
Gero KramerDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Sazan RasulDepartment of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria. sazan.rasul@meduniwien.ac.at.ORCID 0000-0003-2898-3232

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose[

methodsData from 22 male patients with mCRPC, who underwent [

resultsThe majority of metastatic PCa lesions that exhibited PARPi uptake were located in the bones (n = 57), with mean SUVmax values of 4.9 ± 1.5 for PARPi and 30.9 ± 28.3 for [

conclusionResults showed a considerable uptake of [

Indexed as

Antigens, SurfaceEdetic AcidGene Expression Regulation, NeoplasticGlutamate Carboxypeptidase IIPoly(ADP-ribose) Polymerase InhibitorsPositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantUp-RegulationAgedAged, 80 and overFluorine RadioisotopesGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedAntigens, SurfaceEdetic AcidFluorine-18Fluorine RadioisotopesFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIPoly(ADP-ribose) Polymerase Inhibitors18F-PARPimCRPCPET/CTProstate cancerPSMA

Identifiers

PMID40682676
PMCPMC12830453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.